2017 | 02 | 23

Vironova AB signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).

In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body.

Proprietary Vironova Analyzing Software (VAS) in combination with Cryo-transmission electron microscopy (cryoTEM) enables semi-automated image analysis of liposomes, providing accurate, reproducible and timely results.

“Beta-testing is designed to help us accelerate development and improve the robustness and user friendliness of VAS. This is a very valuable compliment to the input from our internal microscopists who work with liposome characterization,” says Nina Ewerlöf, Head of Vironova instruments and software.

The U.S. Food and Drug Administration's National Center for Toxicological Research is a global resource for innovative scientific solutions in support of the agency’s mission to improve public health.

News and events

Read about the latest news and events at Vironova.

  • All news
  • Inside Vironova
  • Open positions
  • Events and publications
VIEW MORE
VIEW MORE
VIEW MORE
VIEW MORE

On demand webinar

  • Title: Unmatched Viral Particle Analysis in Vaccine and Gene Therapy Development
  • Speaker: Josefina Nilsson, head of EM services & Martin Ryner, Strategic development manager
  • Watch webinar

Upcoming events 2017

Cell & Gene Therapy Europe 2017
6-7 December, Amsterdam
Booth 24

Vironova on MyNewsDesk

Follow us on MyNewsDesk and get the latest info on investor relations, events and company news.
Click here to get to our MyNewsDesk-page.

Press contact
For press enquiries, please contact
info@vironova.com

IR contact
Mohammed Homman
ceo@vironova.com